NCOA3 and breast cancer: AIB1 has been broadly investigated in hormone-dependent cancers such as prostate cancer [16], ovarian cancer [17] and uterine endometrial cancers [18] since it was initially discovered to be amplified and overexpressed in breast cancer in 1997 [19].